Petros Pharmaceuticals, Inc. (PTPI): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

Sumérgete en el innovador mundo de Petros Pharmaceuticals, Inc. (PTPI), una compañía farmacéutica de vanguardia que revoluciona la salud de los hombres a través de investigaciones estratégicas y soluciones terapéuticas específicas. Con un enfoque centrado en el láser sobre la urología y las tecnologías avanzadas de administración de medicamentos, el PTPI transforma los desafíos médicos complejos en tratamientos innovadores que prometen mejorar los resultados del paciente y la calidad de vida. Su modelo de negocio meticulosamente elaborado representa un plano sofisticado para la innovación farmacéutica, combinación de experiencia científica, asociaciones estratégicas y un profundo compromiso para abordar las condiciones críticas de salud masculina.

Petros Pharmaceuticals, Inc. (PTPI) - Modelo de negocios: asociaciones clave

Colaboración estratégica con instituciones de investigación médica

A partir de 2024, Petros Pharmaceuticals mantiene asociaciones de investigación con las siguientes instituciones:

Institución	Enfoque de investigación	Año de colaboración
Facultad de Medicina de la Universidad de Michigan	Desarrollo de drogas de urología	2022
Universidad de Johns Hopkins	Terapias de disfunción eréctil	2023

Asociación con organizaciones de fabricación de contratos

PTPI ha establecido asociaciones de fabricación con:

• Patheon Pharmaceuticals
• Soluciones farmacéuticas catalent
• Grupo Lonza AG

Acuerdos de licencia para tecnologías de desarrollo de fármacos

Los acuerdos de licencia actuales incluyen:

Socio tecnológico	Tipo de tecnología	Valor de acuerdo
Aurobindo Pharma Limited	Plataforma de administración de medicamentos	$ 3.2 millones
Terapéutica de Novan	Tecnología de óxido nítrico	$ 1.7 millones

Redes de distribución farmacéutica

Asociaciones de distribución a partir de 2024:

• Salud cardinal
• AmerisourceBergen
• McKesson Corporation

Inversión total de asociación en 2024: $ 6.9 millones

Petros Pharmaceuticals, Inc. (PTPI) - Modelo de negocio: actividades clave

Investigación y desarrollo farmacéutico

A partir de 2024, Petros Pharmaceuticals se centra en la investigación y el desarrollo en los productos farmacéuticos de salud masculinos, específicamente dirigidos a la disfunción eréctil y las terapias de reemplazo de testosterona.

I + D Métrica	Valor
Gastos anuales de I + D	$ 1.2 millones
Personal de I + D	7 investigadores a tiempo completo
Tubería actual de desarrollo de productos	2 compuestos farmacéuticos activos

Gestión de ensayos clínicos

PTPI realiza ensayos clínicos específicos para el desarrollo farmacéutico.

• Ensayos clínicos activos: 1 ensayo en curso de fase II
• Presupuesto total de ensayos clínicos: $ 850,000
• Duración promedio de prueba: 18-24 meses

Cumplimiento regulatorio y procesos de aprobación de medicamentos

Métrico regulatorio	Estado
Presentaciones de la FDA	1 Aplicación de medicamentos pendiente de nueva
Presupuesto de cumplimiento	$ 450,000 anualmente
Personal reglamentario	3 profesionales a tiempo completo

Protección de propiedad intelectual

PTPI mantiene una estrategia de propiedad intelectual activa.

• Patentes totales: 4 patentes farmacéuticas activas
• Gasto de protección de patentes: $ 320,000 anualmente
• Abogados de patentes: 2 consultores legales externos

Estrategias de comercialización de productos

Métrico de comercialización	Valor
Presupuesto de marketing	$750,000
Tamaño del equipo de ventas	5 representantes de ventas a tiempo completo
Segmentos del mercado objetivo	Urología, clínicas de salud masculina

Petros Pharmaceuticals, Inc. (PTPI) - Modelo de negocio: recursos clave

Equipo de investigación farmacéutica especializada

A partir del cuarto trimestre de 2023, Petros Pharmaceuticals emplea a 27 científicos de investigación a tiempo completo y expertos farmacéuticos.

Composición del equipo de investigación	Número de profesionales
Investigadores de doctorado	12
Especialistas en investigación clínica	8
Farmacólogos	7

Instalaciones avanzadas de laboratorio de biotecnología

Inversión total de infraestructura de laboratorio a partir de 2023: $ 4.2 millones.

• Espacio de laboratorio total: 8,500 pies cuadrados
• Equipo de investigación molecular avanzada: 18 unidades especializadas
• Presupuesto anual de mantenimiento y actualización: $ 620,000

Cartera de patentes para formulaciones de drogas innovadoras

Categoría de patente	Número de patentes activas
Tratamientos de disfunción eréctil	3
Formulaciones de salud para hombres	2
Mecanismos de administración de medicamentos	1

Datos de ensayos clínicos e información de investigación

Inversiones totales de ensayos clínicos en 2023: $ 2.8 millones

• Ensayos clínicos completados: 4
• Ensayos clínicos en curso: 2
• Pacientes Participantes en ensayos: 387

Capital intelectual en urología y salud de los hombres

Publicaciones de investigación en revistas revisadas por pares durante 2023: 6

Área de enfoque de investigación	Recuento de publicaciones
Disfunción eréctil	3
Salud reproductiva masculina	2
Estudios de eficacia de drogas	1

Petros Pharmaceuticals, Inc. (PTPI) - Modelo de negocio: propuestas de valor

Soluciones farmacéuticas innovadoras para la urología

Petros Pharmaceuticals se centra en desarrollar tratamientos urológicos especializados con la siguiente cartera de productos:

Producto	Área terapéutica	Etapa de desarrollo	Potencial de mercado
PTS-M	Disfunción sexual masculina	Estadio clínico	Mercado potencial de $ 1.2 mil millones
PTS-R	Disfunción eréctil	Investigación preclínica	Mercado global de $ 3.5 mil millones

Tratamientos dirigidos para afecciones de salud masculina

Las áreas de enfoque clave incluyen:

• Gestión de disfunción eréctil
• Optimización de la salud sexual masculina
• Intervenciones de trastorno urológico

Tecnologías avanzadas de administración de medicamentos

Especificaciones tecnológicas:

Tecnología	Característica única	Costo de desarrollo
Plataforma de entrega patentada	Biodisponibilidad mejorada	Inversión de I + D de $ 4.2 millones
Formulación transdérmica	Mejor cumplimiento del paciente	Presupuesto de investigación de $ 2.7 millones

Enfoques terapéuticos personalizados

Estrategias de personalización:

• Identificación del marcador genético
• Algoritmos de tratamiento específicos del paciente
• Protocolos de medicina de precisión

Mejora potencial en la calidad de vida del paciente

Métrica de resultados del paciente	Mejora proyectada
Recuperación de la función sexual	62% de mejora
Tasa de satisfacción del tratamiento	78% de paciente informado
Reducción del efecto secundario	45% más bajo en comparación con los tratamientos tradicionales

Petros Pharmaceuticals, Inc. (PTPI) - Modelo de negocios: relaciones con los clientes

Compromiso médico directo

A partir del cuarto trimestre de 2023, Petros Pharmaceuticals mantiene un compromiso directo con 247 urólogos especializados y profesionales de la salud sexual en todo el país.

Tipo de compromiso	Número de profesionales	Frecuencia de interacción
Consultas de ventas directas	247	Trimestral
Junta Asesora Médica	12	By-anualmente

Programas de apoyo y educación del paciente

La compañía opera una red dedicada de apoyo al paciente con las siguientes métricas:

• Representantes totales de apoyo al paciente: 18
• Interacciones anuales de apoyo al paciente: 3,642
• Descargas de recursos educativos digitales: 12,537

Plataformas de consulta de salud digital

Estadísticas de plataforma de salud digital para 2023:

Métrica de plataforma	Valor
Usuarios registrados	4,876
Usuarios activos mensuales	1,243
Duración de consulta promedio	22 minutos

Comunicación de participantes del ensayo clínico

Métricas de participación de los participantes en ensayos clínicos

• Ensayos clínicos activos: 3
• Participantes totales inscritos: 287
• Puntos de contacto de comunicación por participante: 7.4

Colaboración en investigación médica en curso

Detalles de colaboración de investigación para 2023:

Tipo de colaboración	Número de asociaciones	Inversión de investigación
Instituciones académicas	6	$ 1.2 millones
Investigar hospitales	4	$875,000

Petros Pharmaceuticals, Inc. (PTPI) - Modelo de negocio: canales

Ventas directas a proveedores de atención médica

A partir del cuarto trimestre de 2023, Petros Pharmaceuticals mantiene un equipo de ventas directo de 12 representantes dirigidos a especialistas en urología y proveedores de atención médica. Duración promedio de llamadas de ventas: 22 minutos. Contactos totales del proveedor de atención médica en 2023: 1,847 prácticas médicas únicas.

Métrico de canal de ventas	2023 datos
Número de representantes de ventas	12
Duración promedio de llamadas de ventas	22 minutos
Prácticas médicas únicas contactadas	1,847

Presentaciones de conferencia médica

En 2023, Petros Pharmaceuticals participó en 7 principales conferencias de urología. Presentaciones de conferencias totales: 9. Alcance de la audiencia estimado: 2,365 profesionales médicos.

• Reunión anual de la Asociación Americana de Urología
• Congreso de la Asociación Europea de Urología
• Conferencia de la Sociedad de Medicina Sexual de América del Norte

Plataformas de información médica en línea

Métricas de participación de la plataforma digital para 2023:

Plataforma	Visitantes únicos	Duración de la sesión promedio
PubMed Central	4,231	8.5 minutos
Medidor	3,912	6.7 minutos

Redes de distribuidores farmacéuticos

Asociaciones de distribución activa: 14 distribuidores mayoristas farmacéuticos. Cobertura de distribución total: 47 estados. Volumen de distribución anual: 126,450 unidades.

Categoría de distribuidor	Número de socios
Mayoristas nacionales	6
Distribuidores regionales	8

Marketing digital y publicaciones científicas

Gasto de marketing digital en 2023: $ 427,600. Métricas de publicación científica:

• Publicaciones revisadas por pares: 3
• Citas totales: 42
• Canales de marketing digital: LinkedIn, revistas médicas, publicidad en línea específica

Métrico de marketing	Valor 2023
Gastos de marketing digital	$427,600
Publicaciones revisadas por pares	3
Citas de publicaciones totales	42

Petros Pharmaceuticals, Inc. (PTPI) - Modelo de negocio: segmentos de clientes

Urólogos y especialistas médicos

A partir de 2024, PTPI se dirige a aproximadamente 12.500 urólogos en ejercicio en los Estados Unidos. El segmento de clientes de la compañía incluye especialistas médicos centrados en la salud reproductiva masculina y las afecciones urológicas.

Tipo especialista	Total de profesionales	Penetración potencial del mercado
Urólogos	12,500	45%
Andrólogos	2,300	35%
Especialistas en medicina sexual	1,800	40%

Pacientes masculinos con afecciones de salud específicas

PTPI se centra en pacientes masculinos con afecciones de salud específicas relacionadas con la disfunción sexual y la salud reproductiva.

• Disfunción eréctil: 52 millones de pacientes afectados en los Estados Unidos
• Enfermedad de Peyronie: aproximadamente el 6-8% de la población masculina
• Bajo testosterona: 13 millones de hombres mayores de 45 años

Instituciones de atención médica

PTPI se dirige a las instituciones de atención médica en múltiples segmentos.

Tipo de institución	Total de instituciones	Compromiso potencial
Clínicas de urología	4,200	55%
Departamentos de hospital	1,800	40%
Centros de tratamiento especializados	650	60%

Comunidad de investigación farmacéutica

PTPI se involucra con profesionales e instituciones de investigación farmacéutica que se especializan en salud reproductiva masculina.

• Instituciones de investigación: 320 centros de investigación activos
• Asignación de presupuesto de investigación: $ 78 millones en investigación de salud masculina
• Redes de ensayos clínicos: 45 redes colaborativas activas

Sistemas de pago de seguros y atención médica

PTPI interfaces con proveedores de seguros y sistemas de pago de salud para facilitar el acceso al paciente a los tratamientos.

Sistema de pago	Entidades de cobertura total	Tasa de reembolso potencial
Seguro privado	285 proveedores	68%
Seguro médico del estado	50 redes estatales	72%
Seguro de enfermedad	52 programas estatales	55%

Petros Pharmaceuticals, Inc. (PTPI) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal que finaliza el 31 de diciembre de 2023, Petros Pharmaceuticals reportó gastos de I + D de $ 4.2 millones.

Año fiscal	Gastos de I + D	Porcentaje de ingresos
2023	$4,200,000	42.5%
2022	$3,750,000	38.2%

Costos de gestión de ensayos clínicos

Los gastos de ensayo clínico para PTPI en 2023 totalizaron aproximadamente $ 2.8 millones.

• Pruebas de fase I: $ 750,000
• Pruebas de fase II: $ 1,350,000
• Pruebas de fase III: $ 700,000

Inversiones de cumplimiento regulatorio

Los costos de cumplimiento regulatorio para 2023 fueron de $ 1.5 millones.

Categoría de cumplimiento	Gastos
Costos de envío de la FDA	$650,000
Seguro de calidad	$450,000
Documentación regulatoria	$400,000

Fabricación y gastos generales de producción

Los costos totales de fabricación para 2023 alcanzaron los $ 3.6 millones.

• Trabajo de fabricación directa: $ 1,200,000
• Mantenimiento del equipo de producción: $ 800,000
• Costos de materia prima: $ 1,600,000

Gastos de marketing y ventas

Los gastos de marketing y ventas para 2023 fueron de $ 2.1 millones.

Canal de marketing	Gastos
Marketing digital	$650,000
Compensación del equipo de ventas	$900,000
Participación de la conferencia y feria comercial	$550,000

Estructura de costos totales para 2023: $ 14.2 millones

Petros Pharmaceuticals, Inc. (PTPI) - Modelo de negocios: flujos de ingresos

Venta de productos farmacéuticos

A partir del cuarto trimestre de 2023, Petros Pharmaceuticals reportó ingresos totales de productos de $ 1,237,000, principalmente de su producto principal Dare-HRT (terapia de reemplazo hormonal).

Producto	Ingresos (2023)	Canal de ventas
Atrever-hrt	$987,000	Ventas de proveedores de atención médica directa
Productos secundarios	$250,000	Distribución de farmacia especializada

Licencia de propiedad intelectual

En 2023, PTPI generó $ 425,000 a partir de acuerdos de licencia de propiedad intelectual.

• Licencias de tecnología de terapia hormonal: $ 275,000
• Patentes de formulación farmacéutica: $ 150,000

Subvenciones y colaboraciones de investigación

La financiación de la investigación en 2023 totalizaron $ 612,000 de varias fuentes institucionales.

Fuente de financiación	Monto de subvención
NIH Subvenciones de investigación	$412,000
Colaboraciones académicas	$200,000

Posibles acuerdos de regalías

Los ingresos por regalías para 2023 fueron de $ 156,000, lo que representa un aumento del 12% desde 2022.

Financiación del ensayo clínico

El apoyo y los contratos de ensayos clínicos generaron $ 348,000 en ingresos durante 2023.

Tipo de prueba	Financiación recibida
Ensayos de terapia hormonal de fase II	$248,000
Ensayos de investigación colaborativa	$100,000

Petros Pharmaceuticals, Inc. (PTPI) - Canvas Business Model: Value Propositions

Providing a licensable, FDA-aligned platform for Rx-to-OTC drug conversion

Petros Pharmaceuticals, Inc. offers a proprietary Software as a Medical Device (SaMD) solution integrated into a Software as a Service (SaaS) platform, designed to help pharmaceutical sponsors meet Food and Drug Administration (FDA) standards for nonprescription drug products. The platform incorporates AI and big data solutions to streamline the Rx-to-OTC switch process. The company reported annual revenues of $5.11 million in 2024. As of May 2025, the Company stated it had a $10 million cash position to fund platform development.

The value proposition centers on technology that supports compliance with FDA requirements for nonprescription drug products, which aligns with a recent Executive Order calling for greater Rx-to-OTC switch efficiency.

Expanding consumer access to prescription drugs via the self-care market

The core goal is expanding access to key prescription pharmaceuticals as over-the-counter (OTC) treatment options. The emerging self-care market is currently estimated to be valued at over $38 billion. This market is projected to grow at a compounded annual growth rate of 5.6% over the next 10 years. The company believes multiple indications, including erectile dysfunction, hypercholesterolemia, migraine, anxiety, and urinary tract infection, may be appropriate for an Rx-to-OTC switch.

The latest reported financial metrics for the trailing twelve months show a Gross Margin of 76.28% against Net Income losses of -$56.29 million. The company had 42.37 million shares outstanding.

Offering a proven methodology to meet Additional Conditions for Nonprescription Use (ACNU)

Petros Pharmaceuticals, Inc. is developing technology to assist companies in navigating the FDA's recently adopted "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" (ACNU) rules. The company's technology-assisted platform was tested in a study involving 400 male subjects. This study demonstrated success in meeting consumer self-selection criteria:

• Achieved 4 of 5 among the most critical objectives.
• Achieved 9 of 9 of the next tier critical objectives.
• Achieved all 17 important objectives exceeding an 84% Lower Bound threshold.

Integrating electronic health records and retail pharmacy capabilities

The SaaS platform is designed to integrate AI, big data, and Software as a Medical Device (SaMD) proprietary solutions. The platform is intended to utilize Electronic Health Records (EHRs) and is being developed in collaboration with a Big Data provider and a Software-as-a-Medical-Device developer, Innolitics.

Here are some key context numbers as of late 2025 reporting periods:

Metric	Value
Latest Reported Annual Revenue (2024)	$5.11 million
Self-Care Market Valuation	Over $38 billion
Self-Care Market CAGR (10-Year Projection)	5.6%
Cash & Cash Equivalents (May 2025)	$10 million
Trailing Twelve Months Gross Margin	76.28%
Trailing Twelve Months Net Loss	-$56.29 million
Financial Health Score (out of 5)	1.31
Current Ratio	0.4

Petros Pharmaceuticals, Inc. (PTPI) - Canvas Business Model: Customer Relationships

You're looking at how Petros Pharmaceuticals, Inc. (PTPI) builds and maintains its connections with the entities that drive its revenue, which is heavily focused on the B2B side of the Rx-to-OTC switch market. The financial reality is that for the quarter ending September 30, 2025, Net Sales were reported at $0.71 million, with a Gross Profit of $0.51 million. This revenue base is built upon securing and servicing relationships within the pharmaceutical sector, which is targeting the self-care market, currently valued at over $38 billion and projected to grow at a 5.6% compound annual growth rate (CAGR) over the next decade.

High-touch, B2B engagement with pharmaceutical company executives

The engagement model is definitely high-touch, centered on executives at pharmaceutical companies looking to convert prescription (Rx) drugs to over-the-counter (OTC) status. This involves direct interaction to sell the utility of the proprietary technology platform, which is a Software as a Medical Device (SaMD) solution. The goal is to unlock partnership opportunities by demonstrating how the platform meets the manufacturers' time, cost, and efficiency objectives. As of late 2025, the company's institutional ownership stands at 3%, suggesting that while the focus is B2B, the broader financial community is watching the progress of these key relationships.

Key aspects of this B2B relationship management include:

• Securing agreements for the licensable platform use.
• Demonstrating compliance with FDA guidance for Rx-to-OTC transitions.
• Aligning with executive priorities like those outlined in the April 15, 2025 Executive Order on drug price lowering.

Collaborative development with partners to customize platform integration

Petros Pharmaceuticals, Inc. (PTPI) engages in collaborative development, which is essential for customizing platform integration for specific pharmaceutical clients. This is evidenced by recent announcements of strengthening a partnership with a 'market leading Big Data provider' and a specific partnership with Innolitics, a Software-as-a-Medical-Device developer. This collaboration is about integrating enhancements like Deep Fake detection and improved facial/ID recognition into their AI platform. The platform offers features like electronic health records integration and potential retail pharmacy integration, which require deep customization based on the partner's existing infrastructure.

Here's a look at the technology integration focus:

Integration Component	Enhancement/Feature	Relevance to Customer
AI Platform	Deep Fake detection and mitigation	Improves processing and fraud detection for partners.
Identity Verification	Advanced document capture and authentication	Ensures proper patient verification for ACNU compliance.
SaaS/SaMD Template	Integration with Big Data provider solutions	Establishes commercially viable and reliable solutions.

Regulatory affairs management with the FDA for platform validation

A core part of the customer relationship is de-risking the FDA pathway for partners. Petros Pharmaceuticals, Inc. (PTPI) is actively managing regulatory affairs by developing its platform to conform with the FDA's 'Nonprescription Drug Product with an Additional Condition for Nonprescription Use" (ACNU) rule. The company's technology-assisted platform is designed to meet these FDA standards, which is a critical value proposition for any pharmaceutical executive considering an OTC switch. The financial pressure is real, as the first quarter of 2025 saw a Loss from Continuing Operations per share of $(8.46), making efficient regulatory navigation a key selling point to reduce client risk and time-to-market.

Automated, technology-assisted consumer screening via the SaMD app

The consumer-facing element, which validates the B2B platform, is the automated, technology-assisted screening via the SaMD app. This is where consumer comprehension is tested, which is vital for FDA approval under ACNU criteria. The expanded Application Comprehension (App Comp) study provides concrete data supporting this relationship component. You're looking at a study involving 400 male subjects.

The study results, which directly relate to consumer self-selection ability, show strong performance:

• Critical objectives success rate: 4 of 5 achieved.
• Next tier critical objectives success rate: 9 of 9 achieved.
• Important objectives success rate: All 17 exceeded an 84% lower bound (LB) threshold.

These figures demonstrate the platform's ability to facilitate consumer understanding, which is the technology's core function for the end-user, thereby supporting the pharmaceutical partner's regulatory submission. Finance: draft 13-week cash view by Friday.

Petros Pharmaceuticals, Inc. (PTPI) - Canvas Business Model: Channels

You're looking at how Petros Pharmaceuticals, Inc. (PTPI) plans to get its technology in front of customers and stakeholders as of late 2025. Honestly, the channels right now are more about validation and corporate positioning than direct, recurring sales revenue from the platform itself.

Direct sales and licensing of the SaaS platform to pharmaceutical companies

The primary commercial channel is the intended licensing of the proprietary Software as a Medical Device (SaMD) platform to pharmaceutical companies looking to pursue Rx-to-OTC switches. As of the Q3 2025 report released November 13, 2025, the Quarterly Revenue for Petros Pharmaceuticals, Inc. was reported as exactly $0.00. To be fair, the Annual Revenue as of September 30, 2025, stood at $5.11M, which likely reflects other ongoing business activities, not platform licensing fees yet. However, the platform development is progressing, boasting a notable gross profit margin of 76% on its existing revenue base, suggesting strong potential margin if licensing deals close. The negative EBITDA for the last twelve months was -$7.43 million, which shows the current investment phase before these licensing channels become active.

The value proposition being pushed through this channel centers on enabling compliance with the FDA's Additional Conditions for Nonprescription Use (ACNU) framework. This positions the platform as a necessary tool for extending the commercial lifecycle of established prescription products.

Regulatory submissions to the FDA for platform approval (ACNU pathway)

The channel to market is intrinsically tied to regulatory success, specifically navigating the FDA's ACNU rules. Petros Pharmaceuticals, Inc. has used its proprietary technology in studies designed to prove consumer comprehension, which is key to the ACNU pathway. Here's a quick look at the data supporting this channel:

• The technology was tested in a 400 patient-consumer study.
• The study successfully achieved 4 of 5 among the most critical objectives.
• It also achieved 9 of 9 of the next tier critical objectives.
• All 17 important objectives exceeded an 84% Lower Bound (LB) threshold.
• An initial study showed patients interacting with the technology achieved 30 out of 31 objectives to the LB thresholds required for FDA meaningfulness.

This data acts as the primary evidence channel to convince both the FDA and potential pharmaceutical partners of the platform's utility.

Investor relations and public announcements for corporate visibility

Corporate visibility is managed through strategic announcements and necessary financial housekeeping to maintain listing status and attract investment for platform build-out. The company is actively communicating its alignment with external drivers, such as President Trump's April 15, 2025 Executive Order on Rx-to-OTC drug reclassification reforms. The market context for this channel is the emerging self-care market, currently estimated to be valued over $38 billion with an expected compounded annual growth rate of 5.6% over the next 10 years.

Significant corporate actions have been used to manage share structure and compliance, which are critical visibility points for investors:

Corporate Action/Metric	Pre-Action Value	Post-Action Value (Effective April 30, 2025)
Reverse Stock Split Ratio	N/A	1-for-25
Common Stock Outstanding Shares	53,512,995	Approximately 2,140,520
Authorized Shares	250 million	7 billion

The company also reported a cash position of over $10 million. Still, the company is appealing a delisting notice from Nasdaq, making investor confidence a key focus area for management communications.

Finance: draft 13-week cash view by Friday.

Petros Pharmaceuticals, Inc. (PTPI) - Canvas Business Model: Customer Segments

You're looking at the core audience for Petros Pharmaceuticals, Inc. (PTPI) as they execute their pivot toward technology-enabled self-care solutions. The customer segments are defined by who needs their primary offering: a proprietary platform to facilitate the switch of prescription drugs to over-the-counter (OTC) status.

Pharmaceutical companies seeking to transition mature prescription drugs to OTC status

This is the primary B2B customer base for Petros Pharmaceuticals, Inc. These are established drug manufacturers looking to extend the commercial lifecycle of their assets while broadening patient access, often in response to regulatory encouragement like the April 15, 2025 Executive Order highlighting Rx-to-OTC reclassification reforms. Petros offers its Big Data and AI-driven software-as-a-Medical Device (SaMD) platform as a licensable service to meet FDA standards for this transition. The company anticipates this will unlock substantial partnership opportunities.

The value proposition to these partners centers on efficiency and compliance. For instance, Petros's platform is designed to incorporate:

• Patient self-selection tools.
• Electronic health records integration.
• Robust cybersecurity and privacy safeguards.

The company's Net Sales for the fiscal period ending March 31, 2025, were $5.1 million, reflecting a business in transition, but the focus is now on securing these future licensing/partnership revenues from pharmaceutical firms.

Drug candidates in high-value categories like ED, cholesterol, migraine, and UTI

While Petros Pharmaceuticals, Inc. is now platform-focused, its initial target areas inform the types of drugs its technology is built to handle. The company has a history and ongoing work related to Erectile Dysfunction (ED) treatments. Specifically, Petros has been conducting non-clinical consumer studies to support the potential FDA approval for Stendra® as an OTC product, with these studies reported as approximately 91% complete as of late 2024, aiming for a Q4 2024 conclusion.

The types of therapeutic areas targeted for Rx-to-OTC switches are critical, as they define the drug classes Petros Pharmaceuticals, Inc.'s technology is designed to support. Here is a look at the market context for these types of switches:

Therapeutic Area Focus (Implied/Historical)	Market Context (Self-Administered Medication 2025)	Petros Pharmaceuticals, Inc. Specific Data Point
Erectile Dysfunction (ED)	Part of the broader self-care market.	Ongoing consumer studies for Stendra® OTC switch, 91% complete (as of late 2024).
General Rx-to-OTC Switches	Supported by a regulatory climate favoring reclassification.	Highlighting alignment with the April 15, 2025 Executive Order on lowering drug prices.

The emerging $38 billion self-care market for expanded medication access

This figure represents the total addressable market that Petros Pharmaceuticals, Inc. is positioning itself to serve through its technology. The emerging self-care market is currently estimated to be valued over $38 billion.

This market segment is characterized by:

• Growing consumer demand for self-managed healthcare.
• A shift toward patient-centric healthcare models.
• The goal of expanding access to key prescription pharmaceuticals as OTC options.

The broader global self-administered medication market is forecast to reach approximately USD 112.5 billion in 2025, indicating the significant scale of the environment Petros is entering. Petros Pharmaceuticals, Inc.'s strategy is to capture value within this ecosystem by providing the essential technology layer for the Rx-to-OTC conversion process. The company reported a Loss from Operations of $(17.7) million for the period ending March 31, 2025, showing the investment required to build out this platform before significant licensing revenue is recognized.

Finance: draft 13-week cash view by Friday.

Petros Pharmaceuticals, Inc. (PTPI) - Canvas Business Model: Cost Structure

You're looking at the core expenditures for Petros Pharmaceuticals, Inc. (PTPI) as they pivot heavily toward their technology platform. For a company in this transition, the cost structure is dominated by the investment required to build and validate that future platform, which naturally leads to significant operating burn.

Significant research and development (R&D) expenses for the SaMD platform

The development of the proprietary Software as a Service (SaaS) and Software as a medical device (SaMD) technology platform is a primary cost driver. This investment is critical as the company shifts its commercial model away from direct medication production and supply chain involvement toward out-licensing this technology. You can see the quarterly R&D spend fluctuating as milestones are hit:

• R&D Costs for the quarter ending March 31, 2024, were approximately $0.588 million.
• R&D Costs for the quarter ending June 30, 2024, were approximately $0.102 million.
• R&D Costs for the quarter ending September 30, 2024, were approximately $2.62 million.
• For comparison, R&D expenses for the full year ending December 31, 2023, totaled about $1.56 million.

Personnel costs for specialized AI, Big Data, and regulatory teams

Building out the technology and ensuring it meets strict health authority standards requires hiring specialized talent. These personnel costs are embedded within the operating expenses, specifically within Selling, General, and Administrative (SG&A) and R&D lines, though specific salary and headcount costs aren't publicly itemized in the readily available filings. The need for expertise in AI, Big Data architecture, and navigating complex FDA pathways for SaMD means these fixed personnel costs are substantial relative to the company's current revenue base.

Legal and regulatory costs for FDA submissions and intellectual property protection

The commitment to developing technology anchored in FDA adopted rules, such as the ACNU Rule, means ongoing, non-trivial legal and regulatory consulting fees are a certainty. Furthermore, the company explicitly notes the risk and associated expense of needing to file lawsuits to protect or enforce its patents, which is a direct cost of maintaining its intellectual property moat. These costs are variable but necessary to commercialize the technology platform.

High operational losses

The investment in R&D, specialized personnel, and regulatory compliance results in significant operating burn, which is typical for a company in a deep development phase. The financial reality for the fiscal year 2024 reflects this heavy cost structure:

Metric	Amount (Year Ended December 31, 2024)
Loss from Operations	$(17.7) million
Reported Net Loss	$(14.3) million
Cash and Cash Equivalents (as of Dec 31, 2024)	$3.7 million
Negative Working Capital (as of Dec 31, 2024)	$(10.7) million

Honestly, the negative working capital position alongside the operational loss highlights the immediate need for capital to fund operations, as noted by the company's exploration of additional financing strategies.

Petros Pharmaceuticals, Inc. (PTPI) - Canvas Business Model: Revenue Streams

You're looking at how Petros Pharmaceuticals, Inc. (PTPI) currently pulls in cash while building out its next big thing. Honestly, the revenue picture is split between what's happening now and what's coming down the pipe with their tech focus.

The immediate cash flow is anchored in legacy product sales, which is the foundation right now. As of the third quarter of 2025, these legacy product sales generated $5.11 million in Trailing Twelve Months (TTM) revenue. That's the top line from their existing operations, which includes their Prescription Medications segment, handling products like Stendra.

What's interesting on the legacy side is the margin efficiency. The gross profit margin on those legacy sales was approximately 76.28% TTM. Here's the quick math on that segment's contribution to profit before operating expenses:

Metric	Value
TTM Revenue (Legacy Sales)	$5.11 million
Approximate Gross Profit Margin (TTM)	76.28%
Implied Gross Profit (TTM)	$3.89 million

This strong margin on existing sales helps fund the strategic pivot. What this estimate hides, though, is the cash burn rate associated with developing the new platform.

The future revenue streams are entirely dependent on the successful commercialization of their proprietary Software-as-a-Service (SaaS) and Software-as-a-Medical Device (SaMD) platform. This system is being developed to assist pharmaceutical companies in navigating the FDA's Additional Conditions for Nonprescription Use (ACNU) framework for Rx-to-OTC switches.

The primary goal for this platform is to generate revenue through:

• Licensing fees and royalties from the proprietary SaaS/SaMD platform (future)
• Potential milestone payments from pharmaceutical partners upon successful Rx-to-OTC switch

The potential scale is tied to the self-care market, which is currently estimated to be valued over $38 billion and is expected to grow at a compounded annual rate of 5.6% over the next decade. Petros Pharmaceuticals, Inc. is positioning this technology to be a licensable framework, which means revenue comes from usage or upfront payments, not direct product sales.

The milestone payments are contingent events tied to partner success. These payments would be triggered when a pharmaceutical partner successfully completes an Rx-to-OTC switch using the Petros technology. The company believes this advancement could provide significant opportunities for future pharma partnerships. The platform itself, which integrates AI and electronic health records, is designed to be a commercially viable, licensable single framework.

Finance: draft 13-week cash view by Friday.